Chadha
T.1, Adlekha
S,2
1Dr.
Tandra Chadha, Associate Professor, Department of Microbiology, 2Dr.
Shashikant Adlekha, Professor and Head, Dept. of Pathology, both authors are
affiliated with Rajshree Medical Research Institute, Bareilly, UP, India.
Corresponding Author:
Dr Tandra Chadha,Associate Professor, E-mail id- ruc.isha@gmail.com
Abstract
Background:
The World Health Organization recommends universal and
quality-controlled screening of blood donations for the major
transfusion-transmissible infections (TTIs): human immunodeficiency
virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and
syphilis. The magnitude of transfusion-transmitted infections (TTI)
varies from country to country depending on TTI’s load in that
particular population. The present study was undertaken to determine
the relative proportion of voluntary donors (VDs) and replacement
donors (RDs) and also, to estimate and compare the seroprevalence and
changing trends of TTIs amongst VDs and RDs in a tertiary care medical
hospital in north India.Methods: This retrospective study was based on
the records of all voluntary and replacement donations whichwere
collected from January 2016to August 2018 in atertiary care medical
college and hospital in Bareilly, Uttar Pradesh, India.Results:Of the
total 7908 donations, 2268 (28.6%) were voluntary and 5640 (71.4%)
werereplacement donation. The overall seroprevalence of TTI was 158
(1.9%) out of total 7908 donations, with prevalence ofhepatitis B virus
(HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV),
were 1.0, 0.8 and 0.1 percent, respectively. Furthermore, the TTIs were
more frequently encountered in RDs in comparison to VDs. Conclusions:
The potential risk of TTIS can be curtailed to a large extent by
increasing in public awareness regarding voluntary blood donation,
donor screening using stringent criteria, counselling anduse of highly
sensitive and specific tests.
Keywords: HBV, HCV, HIV, Seroprevalence, VD, RD
Author Corrected: 25th October 2018 Accepted for Publication: 30th October 2018
Introduction
Material & Methods:
Type of Study: Retrospective study
Place of Study:Tertiary care medical college
hospital in Bareilly, Northern India, from January 2016 to August 2018
Sampling Methods: All records including TTI records,
donor registers, completely filled donor forms, whichincluded the type of
donation (voluntary/replacement), the patient’s details, pre-donation
questionnaire, counselling details and medical examination findings available
for each case were analysed. The samples from all blood donations were screened
for HIV 1-2, HBsAg, HCV, syphilis and malaria. Samples were collected in
vacutainers at the time of blood donation and screened for HIV 1-2, HBsAg and
HCV using fourth-generation enzyme-linked immunosorbent assay (ELISA)
technique, using kits manufactured by Avantor (Bene Sphera, USA) and steps
performed according to kit inserts. All samples with reactive results were
repeated in duplicate before labelling as reactive.
Statistical Methods:All Data were collected for TTI-
HBV, HCV and HIV and analysed.
Results
A
total of 7908 donations were collected during the study period of2
years 8 months (January 2016-August 2018) and comprised 2268 (28.6%)
voluntary and 5640 (71.4%) replacement donations (Table I). The overall
seroprevalence of TTIin donors was 158 (1.9%) out of total 7908
donations, with prevalence ofhepatitis B virus (HBV), hepatitis C virus
(HCV)and human immunodeficiency virus (HIV), were 1.0, 0.8 and 0.1
percentrespectively (Table 2). Further on analysing TTIS amongst VDs
and RDs as shown in Table 3, amongst donors, HBV turned out to be the
most prevalentTTI and the seropositivity for VD and RD were comparable
in year wise category with marked difference note in 2017 HCV cases,
with 0.7% seropositivity in VD and 1.8 % in RD.Conversely,prevalence of
HBV in 2018 in VD was 1.8%, compared to 0.4 % in RD.
Table-1:
Blood donation year wise
Year |
Totaldonations |
Total voluntarydonations, n (%) |
Total replacementdonations, n (%) |
2016 |
1898 |
580(30.5%) |
1318(69.5%) |
2017 |
3404 |
1144(33.6%) |
2260(66.4%) |
2018 |
2606 |
544(20.8%) |
2062(79.2%) |
Total |
7908 |
2268(28.6%) |
5640(71.4%) |
Table
2: Prevalence of HBV, HCV, HIV in blood donors
Year |
Total donation |
HBV, T |
HCV, T |
HIV, T |
2016 |
1898 |
26 |
28 |
2 |
2017 |
3404 |
36 |
16 |
8 |
2018 |
2606 |
20 |
20 |
2 |
T, total number of sero-reactive
units; HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV,
hepatitis B virus
Table-3:Comparison of seroprevalence of human
immunodeficiency virus, hepatitis B virus and hepatitis C virus in voluntary
and replacement donors
Year |
HBsAg |
HCV |
HIV |
|||
|
VD |
RD |
VD |
RD |
VD |
RD |
2016 |
8(1.3%) |
18(1.3%) |
04(0.7%) |
24(1.8%) |
0(0%) |
2(0.1%) |
2017 |
12(1.0%) |
24(1.0%) |
02(0.1%) |
14(0.6%) |
4(0.3%) |
4(0.1%) |
2018 |
10(1.8%) |
10(0.4%) |
4(0.7%) |
16(0.7%) |
0(0%) |
2 |
HIV, human immunodeficiency virus;
HCV, hepatitis C virus; HBsAg, hepatitis B virus surface antigen,VD, Voluntary
Donor, RD, Replacement Donor
Discussion:
Our
results showed that TTIs pose a serious threat to safe blood transfusion andwere
seen in both VD and RD types of donors, with lower to comparable prevalence in
VD compared to RD.Recommendations:Donor
screening using implementation of strict
selection criteria as per the guidelines
laid down for blood banks in the gazette notification by the Government of
India and with use of highly sensitive and advanced techniques for detection of
TTIs , it is possible to decrease the incidence of seropositivity of transfusion-transmitted infections and
improve the blood product safety.
As
the proportion of VD still falls much lower compared to RD, there is an urgent
need to create public awareness regarding voluntary donation and its benefits.
Contribution
of Authors
· Dr Tandra Chadha-Manuscript Writing,
Data Compiling, Literature Review, Final Approval
· Dr Shashikant Adlekha- Manuscript
Editing, Literature Review, Final Approval
Conflicts of Interest:Nil
References
1.
Bihl F, Castelli D, Marincola F, et al. Transfusion-transmitted infections. J Transl Med. 2007;6:5:25.
DOI:10.1186/1479-5876-5-25.[pubmed]
2. ManzoorI,HashmNI,DaudS,AjmalS,FatimaH,RasheedZ,etal.Sero-
prevalenceoftransfusiontransmissibleinfections(TTIS)inblooddonors.Biomedica.2009;25(10):154–8.
3.
Wasfi OA, Sadek NA. Prevalence of hepatitis B surface antigen and hepatitis C
virus antibodies among blood donors in Alexandria, Egypt. East Mediterr Health J. 2011;17(3):238-42.[pubmed]
4.
SaghirSAM,HassanFMA,AlsalahiOSA,AlhariryAEAA,BaqirHS.FrequenciesofHBV,HCV,HIV,andsyphilismarkersamongblooddonors:ahospital-basedstudyinHodeidah,Yemen.Trop J Pharm Res.2012;11(1):132–6.
5.SinghR,VohraP,SinglaP,ChaudharyU.Seroprevalenceoftransfusiontransmissibleinfectionsamonghealthyblooddonorsatgeneralhospital,Sonepath,NorthIndia.J Evol Med Dent Sci.2013;2(26):4816–20.
6.
Chaudhary IA, Samiullah, Khan SS, Masood R, Sardar MA, Mallhi AA.
Seroprevalence of HBV and C among health donors at Fauji Foundation Hospital,
Rawalpindi. Pak Med J 2007;23: 64-7.
7.Mollah
AH, Nahar N, Siddique MA, et al. Common transfusion-transmitted infectious
agents among thalassaemic children in Bangladesh. J Health PopulNutr. 2003 Mar;21(1):67-71.[pubmed]
8. Blood safety, a strategy for the African
region. AFR/RC51/R2. Brazzaville, WHO Regional Office for Africa, 2001.
9. Tapko J.B., Mainuka P., Diarra-Nama A.J.
Status of blood safety in the WHO African Region, report of the 2006 survey.
Brazzaville, WHO Regional Office for Africa, 2009.[pubmed]
10.
Tagny C.T., Owusu-Ofori S., Mbanya D., Deneys V. The blood
donor in sub-Saharan Africa: a review.Transfus Med., 2010;20(1):1–10.[pubmed]
11.
Ward JW, Deppe DA, Samson S, Perkins H, Holland P, Fernando L, et al. Risk of
human immunodeficiency virus infection from blood donors who later developed
the acquired immunodeficiency syndrome. Ann
Intern Med 1987;106:61-28.
12.
Arora D, Arora B, Khetarpal A. Seroprevalence of HIV, HBV, HCV and syphilis in
blood donors in Southern Haryana. Indian J PatholMicrobiol. 2010
Apr-Jun;53(2):308-9. doi: 10.4103/0377-4929.64295.[pubmed]
13.
Singh K, Bhat S, Shastry S. Trend in seroprevalence of Hepatitis B virus
infection among blood donors of coastal Karnataka, India. J Infect Dev Ctries. 2009;3(5):376-9.[pubmed]
14.
Jain A, Rana SS, Chakravarty P, et al. The prevalence of hepatitis C virus
antibodies among the voluntary blood donors of New Delhi, India. Eur J Epidemiol. 2003;18(7):695-7.[pubmed]
15.
Zaraski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost B. Characteristics of
patients with dual infection by hepatitis B and C viruses. J Hepatol.1998;28:27-33.[pubmed]
16.
National Blood Policy 2007, National Aid Control Organization, Ministry of
Health & Family Welfare, Government of India. Available from: www.naco.nic.
in. Accessed 12-03-2013
17.
Country Scenario – an update; National Aids Control Programme India, December
1996
18.
Agarwal VK, Sharma VP, Agrawal P, Gupta D. Sero-prevalence of transfusion
transmissible infections among blood donors in urban area. Asian J Med Res 2012; 1: 112-4.
19.
Gupta N, Kumar V, Kaur A. Seroprevalence of HIV, HBV, HCV and syphilis in
voluntary blood donors. Indian J Med Sci.
2004;58(6):255-7.[pubmed]
20. Jasani
J, Patel V, Bhuva K, Vachhani A, Patel H, Falleiro JJJ. Seroprevalence of
transfusion transmissible infections among blood donors in a tertiary care
hospital. Int J Biol Med Res 2012; 3:
1423-5
21. ChattorajA, Behl R, Kataria VK. Infectious Disease Markers in Blood Donors. Med J Armed Forces India. 2008;64(1):33-5. doi: 10.1016/S0377-1237(08)80142-6. Epub 2011 Jul 21.[pubmed]
How to cite this article?
Chadha T, Adlekha S. Seroprevalence of HBV, HCV and HIV infections in blood donors in voluntary and replacement
donors in a tertiary care hospital in Western Uttar Pradesh, India. Trop J Path Micro 2018;4(6):473-477.doi:10.17511/
jopm.2018.i6.09.